REGN Q2 2019 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.6B-1.9% YoY

Gross Profit

$1.4B87.5% margin

Operating Income

$316M20.0% margin

Net Income

$193M12.2% margin

EPS (Diluted)

$1.68

QoQ Revenue Growth

+14.9%

Cash Flow

Operating Cash Flow

$188M

Free Cash Flow

$94M

Stock-Based Comp.

$106M

Balance Sheet

Total Assets

$13.2B

Total Liabilities

$3.4B

Stockholders' Equity

$9.8B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.6B	-1.9%
Gross Profit	$1.4B	$1.5B	-6.9%
Operating Income	$316M	$622M	-49.3%
Net Income	$193M	$551M	-65.0%

Revenue Segments

Product

$1.2B100%